Background Introduction Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with a five-year survival rate of less than 20%, and treatment options are extremely limited. Traditional targeted drug therapies, such as Sorafenib and other kinase inhibitors, have been used to treat HCC, but their efficacy is limited and diffi...